Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avena sativa pollen extract is an allergenic extract derived from cultivated oat pollen. It is used for the diagnosis (via skin testing) and treatment (via immunotherapy) of allergies to oat pollen. [1, 9] Marketed under the brand name CENTER-AL by ALK-Abello, Inc., it is a non-standardized biologic product. [1, 4] The therapeutic formulation is an alum-precipitated suspension administered via subcutaneous injection. [5, 6] The goal of immunotherapy is to desensitize the patient's immune system to the allergen, thereby reducing the symptoms of the allergy upon natural exposure. [12, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avena sativa pollen extract.